FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4206962825> ?p ?o ?g. }

• W4206962825 endingPage "i374" @default.
• W4206962825 startingPage "i373" @default.
• W4206962825 abstract "Abstract Background Health-related quality of life (HRQOL) is reduced in patients (pts) with ulcerative colitis (UC). We report on the HRQOL benefits of maintenance treatment with upadacitinib (UPA), a selective and reversible Janus kinase inhibitor, in pts with moderately to severely active UC in the Phase, 3 multicentre, randomised, double-blind U-ACHIEVE maintenance study (NCT02819635). Methods This study included a primary analysis of, 451 pts who achieved clinical response following treatment with UPA, 45 mg once daily (QD) in two replicate, 8-week induction studies, U-ACHIEVE induction, and U-ACCOMPLISH (NCT03653026). In U-ACHIEVE maintenance, pts from both induction studies were re-randomised, 1:1:1 to receive QD UPA, 15 mg, UPA, 30 mg, or PBO. HRQOL outcomes evaluated included the percent of pts reporting a clinically meaningful within-person change (MWPC) from induction baseline to Week, 0 (maintenance baseline) and Week, 52 (end of maintenance) in a broad range of HRQOL measures, including Inflammatory Bowel Disease Questionnaire (IBDQ), Work Productivity and Impairment Questionnaire (WPAI), Short Form, 36 (SF-36), European Quality of Life-5 Dimensions, 5 Levels (EQ-5D-5L), and Ulcerative Colitis Symptoms Questionnaire (UC-SQ). Results A total of, 149, 148, and, 154 pts received PBO, UPA, 15 mg, and UPA, 30 mg QD, respectively, during maintenance. At Week, 0 of the maintenance study, there were no significant differences between UPA and PBO treatment groups in the percentage of pts reporting MWPC relative to induction baseline for most pt-reported outcomes (PROs) as all pts enrolled in maintenance were UPA clinical responders during IP. For IBDQ, a significantly greater proportion of pts achieved MWPC criteria (p&lt;0.001) with UPA, 15 mg (68.9%) and UPA, 30 mg (78.6%) vs, 39.6% for PBO at Week, 52 (Figure, 1). Also, a significantly greater proportion of pts treated with either, 15 mg or, 30 mg UPA dosage vs PBO over, 52 weeks achieved MWPC for the WPAI domains (p≤0.01) of overall work improvement, presenteeism, and activity impairment (Figure, 2), in both physical and mental component summaries of SF-36 (p&lt;0.001, Figure, 3), in EQ-5D-5L (p&lt;0.001, Figure, 4), and in UC-SQ (p&lt;0.001). A numerically greater proportion of pts receiving UPA, 30 mg vs, 15 mg achieved MWPC in most PROs at Week 52. Conclusion A significantly higher percentage of pts with moderately to severely active UC who responded to UPA induction therapy maintained clinically meaningful improvements with UPA, 15 mg of, 30 mg compared to PBO consistently across a broad range of HRQOL outcomes after, 52 weeks of maintenance treatment. These HRQOL aspects include IBD symptoms (IBDQ, UC-SQ), work productivity (WPAI), physical and mental functioning (SF-36), and general well-being (IBDQ, EQ-5D)." @default.
• W4206962825 created "2022-01-26" @default.
• W4206962825 creator A5026012636 @default.
• W4206962825 creator A5040354010 @default.
• W4206962825 creator A5040693774 @default.
• W4206962825 creator A5054825914 @default.
• W4206962825 creator A5056735741 @default.
• W4206962825 creator A5057854630 @default.
• W4206962825 creator A5064013442 @default.
• W4206962825 creator A5068100543 @default.
• W4206962825 creator A5081674539 @default.
• W4206962825 creator A5084914098 @default.
• W4206962825 creator A5090598423 @default.
• W4206962825 date "2022-01-01" @default.
• W4206962825 modified "2023-10-08" @default.
• W4206962825 title "P370 Maintenance of health-related quality of life improvements with upadacitinib treatment among patients with moderately to severely active ulcerative colitis: results from, 52-week phase, 3 study U ACHIEVE maintenance" @default.
• W4206962825 doi "https://doi.org/10.1093/ecco-jcc/jjab232.497" @default.
• W4206962825 hasPublicationYear "2022" @default.
• W4206962825 type Work @default.
• W4206962825 citedByCount "2" @default.
• W4206962825 countsByYear W42069628252022 @default.
• W4206962825 countsByYear W42069628252023 @default.
• W4206962825 crossrefType "journal-article" @default.
• W4206962825 hasAuthorship W4206962825A5026012636 @default.
• W4206962825 hasAuthorship W4206962825A5040354010 @default.
• W4206962825 hasAuthorship W4206962825A5040693774 @default.
• W4206962825 hasAuthorship W4206962825A5054825914 @default.
• W4206962825 hasAuthorship W4206962825A5056735741 @default.
• W4206962825 hasAuthorship W4206962825A5057854630 @default.
• W4206962825 hasAuthorship W4206962825A5064013442 @default.
• W4206962825 hasAuthorship W4206962825A5068100543 @default.
• W4206962825 hasAuthorship W4206962825A5081674539 @default.
• W4206962825 hasAuthorship W4206962825A5084914098 @default.
• W4206962825 hasAuthorship W4206962825A5090598423 @default.
• W4206962825 hasBestOaLocation W42069628251 @default.
• W4206962825 hasConcept C126322002 @default.
• W4206962825 hasConcept C159110408 @default.
• W4206962825 hasConcept C1862650 @default.
• W4206962825 hasConcept C2776694085 @default.
• W4206962825 hasConcept C2778260677 @default.
• W4206962825 hasConcept C2778283404 @default.
• W4206962825 hasConcept C2779134260 @default.
• W4206962825 hasConcept C2779951463 @default.
• W4206962825 hasConcept C2780479503 @default.
• W4206962825 hasConcept C27924281 @default.
• W4206962825 hasConcept C3019006561 @default.
• W4206962825 hasConcept C71924100 @default.
• W4206962825 hasConceptScore W4206962825C126322002 @default.
• W4206962825 hasConceptScore W4206962825C159110408 @default.
• W4206962825 hasConceptScore W4206962825C1862650 @default.
• W4206962825 hasConceptScore W4206962825C2776694085 @default.
• W4206962825 hasConceptScore W4206962825C2778260677 @default.
• W4206962825 hasConceptScore W4206962825C2778283404 @default.
• W4206962825 hasConceptScore W4206962825C2779134260 @default.
• W4206962825 hasConceptScore W4206962825C2779951463 @default.
• W4206962825 hasConceptScore W4206962825C2780479503 @default.
• W4206962825 hasConceptScore W4206962825C27924281 @default.
• W4206962825 hasConceptScore W4206962825C3019006561 @default.
• W4206962825 hasConceptScore W4206962825C71924100 @default.
• W4206962825 hasIssue "Supplement_1" @default.
• W4206962825 hasLocation W42069628251 @default.
• W4206962825 hasOpenAccess W4206962825 @default.
• W4206962825 hasPrimaryLocation W42069628251 @default.
• W4206962825 hasRelatedWork W1559779985 @default.
• W4206962825 hasRelatedWork W2021359433 @default.
• W4206962825 hasRelatedWork W2031018501 @default.
• W4206962825 hasRelatedWork W2070285775 @default.
• W4206962825 hasRelatedWork W2408939568 @default.
• W4206962825 hasRelatedWork W2416132524 @default.
• W4206962825 hasRelatedWork W2418837291 @default.
• W4206962825 hasRelatedWork W2739248189 @default.
• W4206962825 hasRelatedWork W2765379856 @default.
• W4206962825 hasRelatedWork W1581389539 @default.
• W4206962825 hasVolume "16" @default.
• W4206962825 isParatext "false" @default.
• W4206962825 isRetracted "false" @default.
• W4206962825 workType "article" @default.